Pfizer, Inc. · NYSE:PFE
Pfizer — Citi 2014 Global Healthcare Conference
6 slides from Pfizer's conference presentation, Feb 25, 2014
Slide 1: Pfizer R&D Update
Pfizer R&D Update Mikael Dolsten, M.D., Ph.D. President, Worldwide R&D EVP, Pfizer Inc. February 25, 2014
Slide 2: Forward-Looking Statements and Non-GAAP Financial Information
Forward-Looking Statements and Non-GAAP Financial Information • Our discussions during this meeting will include forward-looking statements. Actual results could differ materially from those projected in the forward-looking statements. The factors that could cause actual results to differ are discus
Slide 3: R&D Turnaround Delivering Increased Productivity
R&D Turnaround Delivering Increased Productivity Increased focus, rigor and discipline in R&D Investments in pipeline, capabilities, new science and talent base Relocation to key biomedical hubs complete Strengthened technical platforms Biologic, small molecule and vaccine design, Precision Medicine
Slide 4: Reaching New Patients/Geographies with Recent Launches
Reaching New Patients/Geographies with Recent Launches Recent Launches Expansion Opportunities Prevention of pneumococcal disease in • Pneumococcal disease prevention in adults children & adults • Phase 3 in Psoriasis, Ulcerative Colitis, Psoriatic Treatment of moderate Arthritis to severe RA • Phas
Slide 5: Innovative Next Wave Across Key Therapeutic Areas
Innovative Next Wave Across Key Therapeutic Areas Key Phase 3 Programs Key Earlier Programs • Palbociclib: Breast Cancer • Inlyta, ALK1: Liver Cancer Trastuzumab*: Breast Cancer • SMO: Blood Cancer • ALK/ROS 2nd Gen: NSCLC • 41BB & ADC MAbs • Staph aureus Vaccine • Meningococcal B Vaccine • C. diffi
Slide 6: Q&A
Q&A